CD274 and non-small cell lung carcinoma: In a NSCLC xenograft model, treatment with the anti-PD-L1 CAR-T, δ-TCRγδ-T or γ-TCRγδ-T cells generated from two different donors effectively suppressed tumor progression for up to 46 days after infusion (Fig. 3A and Supplementary Fig. 2).